Review



soluble endoglin quantikine assay  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    R&D Systems soluble endoglin quantikine assay
    Circulating vascular injury and angiogenesis biomarkers after coronavirus disease 2019 (COVID‐19) infection. Plasma samples from healthy controls (0; n = 29), patients whose maximal respiratory support was supplemental oxygen (4, 5, 6; n = 49), and patients who required assisted ventilation (7, 8, 9; n = 22) were assessed for the following analytes using MesoScale Discovery multiplex immunoassays. (a) Serum amyloid A (SAA); (b) C‐reactive protein (CRP); (c) intercellular adhesion molecule 1 (ICAM‐1); (d) vascular cell adhesion molecule 1 (VCAM‐1); (e) E‐selectin; (f) thrombomodulin; (g) vascular endothelial growth factor A (VEGF‐A); (h) VEGFR1/Flt‐1; (i) placental growth factor (PlGF); (j) fibroblast growth factor (basic) (FGF(b)); (k) Tie‐2; (l) soluble <t>endoglin</t> (sENG) enzyme‐linked immunosorbent assay (ELISA); (m) bone morphogenetic protein 9 (BMP9) ELISA; (n) prodomain BMP10 (pBMP10) ELISA; (o) Pearson's correlation of circulating BMP9 and pBMP10 levels. p = 0.7415; (p) number of days patients were administered dexamethasone treatment before sample receipt; (q) Pearson's correlation of circulating BMP9 levels and dexamethasone treatment length. p = 0.3052; (r) circulating BMP9 levels of patient groups separated upon the time taken to be enrolled into the study. Sample receipt ≤7 days versus >7 days. All data presented as median–interquartile range. Kruskal–Wallis test. Dunn's multiple comparison test. ns, not significant; WHO, World Health Organization. p Values = *0.05; **0.01; ***0.001; ****0.0001.
    Soluble Endoglin Quantikine Assay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/soluble endoglin quantikine assay/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    soluble endoglin quantikine assay - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Reduced circulating BMP9 and pBMP10 in hospitalized COVID‐19 patients"

    Article Title: Reduced circulating BMP9 and pBMP10 in hospitalized COVID‐19 patients

    Journal: Pulmonary Circulation

    doi: 10.1002/pul2.12192

    Circulating vascular injury and angiogenesis biomarkers after coronavirus disease 2019 (COVID‐19) infection. Plasma samples from healthy controls (0; n = 29), patients whose maximal respiratory support was supplemental oxygen (4, 5, 6; n = 49), and patients who required assisted ventilation (7, 8, 9; n = 22) were assessed for the following analytes using MesoScale Discovery multiplex immunoassays. (a) Serum amyloid A (SAA); (b) C‐reactive protein (CRP); (c) intercellular adhesion molecule 1 (ICAM‐1); (d) vascular cell adhesion molecule 1 (VCAM‐1); (e) E‐selectin; (f) thrombomodulin; (g) vascular endothelial growth factor A (VEGF‐A); (h) VEGFR1/Flt‐1; (i) placental growth factor (PlGF); (j) fibroblast growth factor (basic) (FGF(b)); (k) Tie‐2; (l) soluble endoglin (sENG) enzyme‐linked immunosorbent assay (ELISA); (m) bone morphogenetic protein 9 (BMP9) ELISA; (n) prodomain BMP10 (pBMP10) ELISA; (o) Pearson's correlation of circulating BMP9 and pBMP10 levels. p = 0.7415; (p) number of days patients were administered dexamethasone treatment before sample receipt; (q) Pearson's correlation of circulating BMP9 levels and dexamethasone treatment length. p = 0.3052; (r) circulating BMP9 levels of patient groups separated upon the time taken to be enrolled into the study. Sample receipt ≤7 days versus >7 days. All data presented as median–interquartile range. Kruskal–Wallis test. Dunn's multiple comparison test. ns, not significant; WHO, World Health Organization. p Values = *0.05; **0.01; ***0.001; ****0.0001.
    Figure Legend Snippet: Circulating vascular injury and angiogenesis biomarkers after coronavirus disease 2019 (COVID‐19) infection. Plasma samples from healthy controls (0; n = 29), patients whose maximal respiratory support was supplemental oxygen (4, 5, 6; n = 49), and patients who required assisted ventilation (7, 8, 9; n = 22) were assessed for the following analytes using MesoScale Discovery multiplex immunoassays. (a) Serum amyloid A (SAA); (b) C‐reactive protein (CRP); (c) intercellular adhesion molecule 1 (ICAM‐1); (d) vascular cell adhesion molecule 1 (VCAM‐1); (e) E‐selectin; (f) thrombomodulin; (g) vascular endothelial growth factor A (VEGF‐A); (h) VEGFR1/Flt‐1; (i) placental growth factor (PlGF); (j) fibroblast growth factor (basic) (FGF(b)); (k) Tie‐2; (l) soluble endoglin (sENG) enzyme‐linked immunosorbent assay (ELISA); (m) bone morphogenetic protein 9 (BMP9) ELISA; (n) prodomain BMP10 (pBMP10) ELISA; (o) Pearson's correlation of circulating BMP9 and pBMP10 levels. p = 0.7415; (p) number of days patients were administered dexamethasone treatment before sample receipt; (q) Pearson's correlation of circulating BMP9 levels and dexamethasone treatment length. p = 0.3052; (r) circulating BMP9 levels of patient groups separated upon the time taken to be enrolled into the study. Sample receipt ≤7 days versus >7 days. All data presented as median–interquartile range. Kruskal–Wallis test. Dunn's multiple comparison test. ns, not significant; WHO, World Health Organization. p Values = *0.05; **0.01; ***0.001; ****0.0001.

    Techniques Used: Infection, Multiplex Assay, Enzyme-linked Immunosorbent Assay, Comparison



    Similar Products

    soluble endoglin quantikine assay  (R&D Systems)
    90
    R&D Systems soluble endoglin quantikine assay
    Circulating vascular injury and angiogenesis biomarkers after coronavirus disease 2019 (COVID‐19) infection. Plasma samples from healthy controls (0; n = 29), patients whose maximal respiratory support was supplemental oxygen (4, 5, 6; n = 49), and patients who required assisted ventilation (7, 8, 9; n = 22) were assessed for the following analytes using MesoScale Discovery multiplex immunoassays. (a) Serum amyloid A (SAA); (b) C‐reactive protein (CRP); (c) intercellular adhesion molecule 1 (ICAM‐1); (d) vascular cell adhesion molecule 1 (VCAM‐1); (e) E‐selectin; (f) thrombomodulin; (g) vascular endothelial growth factor A (VEGF‐A); (h) VEGFR1/Flt‐1; (i) placental growth factor (PlGF); (j) fibroblast growth factor (basic) (FGF(b)); (k) Tie‐2; (l) soluble <t>endoglin</t> (sENG) enzyme‐linked immunosorbent assay (ELISA); (m) bone morphogenetic protein 9 (BMP9) ELISA; (n) prodomain BMP10 (pBMP10) ELISA; (o) Pearson's correlation of circulating BMP9 and pBMP10 levels. p = 0.7415; (p) number of days patients were administered dexamethasone treatment before sample receipt; (q) Pearson's correlation of circulating BMP9 levels and dexamethasone treatment length. p = 0.3052; (r) circulating BMP9 levels of patient groups separated upon the time taken to be enrolled into the study. Sample receipt ≤7 days versus >7 days. All data presented as median–interquartile range. Kruskal–Wallis test. Dunn's multiple comparison test. ns, not significant; WHO, World Health Organization. p Values = *0.05; **0.01; ***0.001; ****0.0001.
    Soluble Endoglin Quantikine Assay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/soluble endoglin quantikine assay/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    soluble endoglin quantikine assay - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Circulating vascular injury and angiogenesis biomarkers after coronavirus disease 2019 (COVID‐19) infection. Plasma samples from healthy controls (0; n = 29), patients whose maximal respiratory support was supplemental oxygen (4, 5, 6; n = 49), and patients who required assisted ventilation (7, 8, 9; n = 22) were assessed for the following analytes using MesoScale Discovery multiplex immunoassays. (a) Serum amyloid A (SAA); (b) C‐reactive protein (CRP); (c) intercellular adhesion molecule 1 (ICAM‐1); (d) vascular cell adhesion molecule 1 (VCAM‐1); (e) E‐selectin; (f) thrombomodulin; (g) vascular endothelial growth factor A (VEGF‐A); (h) VEGFR1/Flt‐1; (i) placental growth factor (PlGF); (j) fibroblast growth factor (basic) (FGF(b)); (k) Tie‐2; (l) soluble endoglin (sENG) enzyme‐linked immunosorbent assay (ELISA); (m) bone morphogenetic protein 9 (BMP9) ELISA; (n) prodomain BMP10 (pBMP10) ELISA; (o) Pearson's correlation of circulating BMP9 and pBMP10 levels. p = 0.7415; (p) number of days patients were administered dexamethasone treatment before sample receipt; (q) Pearson's correlation of circulating BMP9 levels and dexamethasone treatment length. p = 0.3052; (r) circulating BMP9 levels of patient groups separated upon the time taken to be enrolled into the study. Sample receipt ≤7 days versus >7 days. All data presented as median–interquartile range. Kruskal–Wallis test. Dunn's multiple comparison test. ns, not significant; WHO, World Health Organization. p Values = *0.05; **0.01; ***0.001; ****0.0001.

    Journal: Pulmonary Circulation

    Article Title: Reduced circulating BMP9 and pBMP10 in hospitalized COVID‐19 patients

    doi: 10.1002/pul2.12192

    Figure Lengend Snippet: Circulating vascular injury and angiogenesis biomarkers after coronavirus disease 2019 (COVID‐19) infection. Plasma samples from healthy controls (0; n = 29), patients whose maximal respiratory support was supplemental oxygen (4, 5, 6; n = 49), and patients who required assisted ventilation (7, 8, 9; n = 22) were assessed for the following analytes using MesoScale Discovery multiplex immunoassays. (a) Serum amyloid A (SAA); (b) C‐reactive protein (CRP); (c) intercellular adhesion molecule 1 (ICAM‐1); (d) vascular cell adhesion molecule 1 (VCAM‐1); (e) E‐selectin; (f) thrombomodulin; (g) vascular endothelial growth factor A (VEGF‐A); (h) VEGFR1/Flt‐1; (i) placental growth factor (PlGF); (j) fibroblast growth factor (basic) (FGF(b)); (k) Tie‐2; (l) soluble endoglin (sENG) enzyme‐linked immunosorbent assay (ELISA); (m) bone morphogenetic protein 9 (BMP9) ELISA; (n) prodomain BMP10 (pBMP10) ELISA; (o) Pearson's correlation of circulating BMP9 and pBMP10 levels. p = 0.7415; (p) number of days patients were administered dexamethasone treatment before sample receipt; (q) Pearson's correlation of circulating BMP9 levels and dexamethasone treatment length. p = 0.3052; (r) circulating BMP9 levels of patient groups separated upon the time taken to be enrolled into the study. Sample receipt ≤7 days versus >7 days. All data presented as median–interquartile range. Kruskal–Wallis test. Dunn's multiple comparison test. ns, not significant; WHO, World Health Organization. p Values = *0.05; **0.01; ***0.001; ****0.0001.

    Article Snippet: Enzyme‐linked immunosorbent assays (ELISAs) for BMP9 and pBMP10 were conducted as previously described., The soluble endoglin Quantikine assay (R&D Systems) was performed according to the manufacturer's instructions.

    Techniques: Infection, Multiplex Assay, Enzyme-linked Immunosorbent Assay, Comparison